Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/76388
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fox, S. | - |
dc.contributor.author | Kumarasinghe, M. | - |
dc.contributor.author | Armes, J. | - |
dc.contributor.author | Bilous, M. | - |
dc.contributor.author | Cummings, M. | - |
dc.contributor.author | Farshid, G. | - |
dc.contributor.author | Fitzpatrick, N. | - |
dc.contributor.author | Francis, G. | - |
dc.contributor.author | McCloud, P. | - |
dc.contributor.author | Raymond, W. | - |
dc.contributor.author | Morey, A. | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | American Journal of Surgical Pathology, 2012; 36(4):577-582 | - |
dc.identifier.issn | 0147-5185 | - |
dc.identifier.issn | 1532-0979 | - |
dc.identifier.uri | http://hdl.handle.net/2440/76388 | - |
dc.description.abstract | rastuzumab provides a survival benefit in patients with human epidermal growth factor receptor 2 (HER2)-amplified/overexpressed advanced gastric and gastroesophageal junction cancers (GC/GJCs). However, the optimal method for testing is unclear. The aim of this study was to assess interlaboratory agreement on HER2 scoring in GC/GJC to aid the development of a robust testing algorithm for diagnostic practice in Australia. Nine laboratories assessed the HER2 status of 100 GC/GJC tissue samples by immunohistochemistry (IHC) and in situ hybridization (ISH) [chromogenic (CISH) or silver (SISH)] using both HER2 copy number and HER2:chr17 (chromosome 17) ratio. Results were compared with reference fluorescence ISH (FISH). Interlaboratory agreement on IHC3+ scoring was good ([kappa]=0.76), and there was good/very good agreement between IHC (positivity defined as IHC3+) and ISH when HER2 copy number was used ([kappa]=0.72 to 0.87). Agreement on CISH/SISH scoring was good/very good when HER2 copy number was used ([kappa]=0.68 to 0.86), and agreement between CISH/SISH and FISH using HER2 copy number was very good ([kappa]=0.88 to 0.91). Agreement was reduced when HER2:chr17 ratio was used. The good agreement for HER2 copy number determined by bright-field ISH suggests that this is the optimal method for testing in GC/GJC cases. An IHC3+ score was strongly predictive of a positive ISH result, although agreement for all IHC scores was only moderate, suggesting that IHC triage before ISH testing would be the most cost-effective strategy. However, because of the unique features of GC/GJC samples and the difficulty of ensuring consistent HER2 staining in the community setting, it is recommended that HER2 status in advanced GC/GJC be determined by both IHC and ISH in the same laboratory. | - |
dc.description.statementofresponsibility | Stephen B. Fox, Marian Priyanthi Kumarasinghe, Jane E. Armes, Michael Bilous, Margaret C. Cummings, Gelareh Farshid, Nicole Fitzpatrick, Philip I. McCloud, Wendy Ann Raymond and Adrienne Morey | - |
dc.language.iso | en | - |
dc.publisher | Lippincott Williams & Wilkins | - |
dc.rights | © 2012 by Lippincott Williams & Wilkins | - |
dc.source.uri | http://dx.doi.org/10.1097/pas.0b013e318244adbb | - |
dc.subject | HER2 | - |
dc.subject | immunohistochemistry | - |
dc.subject | in situ hybridization | - |
dc.subject | gastric cancer | - |
dc.subject | trastuzumab | - |
dc.title | Gastric HER2 Testing Study (GaTHER): An Evaluation of Gastric/Gastroesophageal Junction Cancer Testing Accuracy in Australia | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1097/PAS.0b013e318244adbb | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Farshid, G. [0000-0002-2056-0561] | - |
Appears in Collections: | Aurora harvest Pathology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.